What is Proton Therapy
Read our Covid-19 policy

Call Now For More Information

General Questions or
Schedule an Appointment


Current Patients


Physician Line


Read our Covid-19 policy

Stampede Trial for Advanced Metastatic Prostate Cancer

Exciting New Treatment Options for Men with Limited Metastatic Prostate Cancer

A recent ongoing trial discovered new treatment options for men with limited metastatic prostate cancer. Results from the STAMPEDE trial suggest that if a patient’s cancer has only spread to a few sites beyond the prostate, they could live longer if the prostate is treated with radiation therapy. This is the first high-quality evidence from a randomized clinical trial to suggest that it’s possible to prolong survival even if the cancer has already metastasized. There is increasing evidence that a small group of patients with limited metastatic prostate cancer could benefit from aggressively treating the visible sites of cancer with radiation therapy or surgery. Men who fall into this category should consider adding radiation treatment to the prostate in addition to their systemic therapy (typically hormone therapy). Patients with metastatic cancer are living longer because improved systemic therapies such as chemotherapy, immunotherapy, and hormone therapy are doing a better job of killing cancer cells.

Additionally, while the duration of treatment is different for every individual, radiation treatment for limited metastatic prostate cancer typically mirrors that of non-metastatic prostate cancer and is similarly effective against prostate cancer. However, patients will still need systemic therapy to treat the cancer outside the prostate. Patients choosing proton therapy will continue to reap the benefits associated with the modality: less damage to healthy tissue than traditional radiation treatment for prostate cancer, including the bladder, rectum, and body in general.

In order to be considered for this new treatment, patients must meet specific criteria: the diagnosis of limited metastatic prostate cancer must be relatively new, patients should have started hormone therapy less than a year ago, patients cannot have received prior radiation for prostate cancer, and their PSA should have responded well to hormone therapy.

Are you a candidate for this treatment?

If you have limited metastatic prostate cancer and would like to find out if proton therapy treatment is appropriate for you, call or email us.
Phone: 1-855-528-7248
Email: intake@seattleprotons.org

About the STAMPEDE Trial

STAMPEDE (Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy) is a large clinical trial that is assessing new treatments for men with high-risk prostate cancer. The trial has been open since 2005 and some results have been released, including observations related to patients with limited metastatic prostate cancer. Each new or alternative treatment is compared with the current standard approach, referred to as a “comparison.” More than 10,000 people have joined STAMPEDE so far; more findings will become available as the trial continues.